Latanoprost-Netarsudil Ophthalmic

Latanoprost-Netarsudil Ophthalmic is a combination medication used for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

• Latanoprost-Netarsudil Ophthalmic is available under the following different brand names: Rocklatan

Common side effects of Latanoprost-Netarsudil Ophthalmic include:

• eye redness
• instillation site pain
• a whorl-like pattern of golden brown or gray deposits in the eye (corneal verticillata)
• broken blood vessels in the eye

Serious side effects of Latanoprost-Netarsudil Ophthalmic include:

• vision changes
• eye pain
• unusual redness
• swelling of the eyes/eyelids

Rare side effects of Latanoprost-Netarsudil Ophthalmic include:

• none

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, coordination loss, unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, light-headedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Ophthalmic solution

• 0.02 %/0.005 % (0.2 mg/mL and 0.05 mg/mL)
• Bottle: 2.5 mL fill in 4 mL container

Elevated Intraocular Pressure

Adult dosage

• Instill 1 drop in affected eye(s) once daily in the evening; not to exceed 1 dose/day

Dosage Considerations – Should be Given as Follows:

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, healthcare provider, or pharmacist first.

• Latanoprost-Netarsudil Ophthalmic has severe interactions with no other drugs
• Latanoprost-Netarsudil Ophthalmic has serious interactions with the following drugs:
  • bimatoprost
  • latanoprostene bunod ophthalmic
  • tafluprost
  • travoprost ophthalmic
• Latanoprost-Netarsudil Ophthalmic has moderate interactions with at least 31 other drugs
• Latanoprost-Netarsudil Ophthalmic has minor interactions with no other drugs

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, health questions, or concerns.

Contraindications

• None

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Latanoprost-Netarsudil Ophthalmic?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Latanoprost-Netarsudil Ophthalmic?”

Cautions

• Latanoprost reported to cause changes to pigmented tissues (owing to increased melanin content in melanocytes), including increased pigmentation of the iris, periorbital tissue, and eyelashes; pigmentation is expected to increase as long as latanoprost is administered; inform patients of the possibility of increased pigmentation
• Latanoprost may gradually change eyelashes and vellus hair in the treated eye; changes include increased length, thickness, pigmentation, number of lashes or hairs, and misdirected growth of eyelashes; eyelash changes are usually reversible when treatment discontinued
• Caution with a history of intraocular inflammation (iritis/uveitis); should generally not be used with active intraocular inflammation because latanoprost may exacerbate inflammation
• Macular edema, including cystoid macular edema, reported with latanoprost; caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or those with known risk factors for macular edema
• Reactivation of herpes simplex keratitis reported with latanoprost; caution with history of herpetic keratitis; avoid with active herpes simplex keratitis as the administration may exacerbate inflammation
• Risk of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products
• Remove contact lenses before administration
• Drug interaction overview
  • In vitro, studies show precipitation of latanoprost solution occurs when mixed with thimerosal-containing ophthalmic drops
  • Combining 2 or more prostaglandins or prostaglandin analogues is not recommended; administration of prostaglandin drug products more than once daily may mitigate the IOP-lowering effect or cause paradoxical elevations in IOP

Pregnancy and Lactation

• There are no available data regarding ophthalmic use in pregnant women
• Lactation
  • No data are available regarding the presence of netarsudil or latanoprost in human milk, the effects on the breastfed infant, or milk production
  • Systemic exposure to netarsudil following topical ocular administration is low, and it is not known whether measurable levels of netarsudil would be present in maternal milk following topical ocular administration
  • Consider the development and health benefits of breastfeeding along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition